Last updated: May 29, 2026
XOFLUZA suppliers: who manufactures the active ingredient and finished tablets (and where are the key contract manufacturers)
XOFLUZA (baloxavir marboxil) supply chain is anchored by the drug’s small-molecule API and solid oral finished-dose manufacturing under global licensing and contract manufacturing. The supplier set used for commercialization typically splits into (1) baloxavir marboxil API supply, (2) finished-dose tablet manufacturing, and (3) packaging and distribution network for the FDA-marketed product.
Answer (executive summary): XOFLUZA is not a “single-supplier” program. It relies on at least one specialized API supply and one or more finished-dose CDMOs in the tablet value chain, with regional packaging/distribution partners supporting US launches and replenishment. To identify named suppliers, the controlling sources are the FDA Drug Master File (DMF) holders for baloxavir marboxil and the Orange Book label/manufacturer listed for NDA/NDC codes, plus procurement disclosures in legal settlements and commercial filings tied to the NDA.
No complete and accurate, named list of suppliers (API holder, tablet manufacturer, packaging house) can be produced from the information available in this chat.
Who supplies the baloxavir marboxil API for XOFLUZA?
API suppliers for baloxavir marboxil are typically disclosed through DMF ownership and through the NDA’s manufacturing section in FDA reviews, not through marketing materials. For contract-manufactured APIs, DMF holders and associated manufacturing sites are the most reliable supplier identifiers.
Which DMF holders typically control baloxavir marboxil
For XOFLUZA, the practical way to build an “API supplier” list is:
- Identify the DMF(s) for baloxavir marboxil used in the FDA approval package.
- Map DMF holders to listed manufacturing sites.
- Cross-check against commercial NDC manufacturing/labeler data in the FDA Orange Book/NDC directory.
What contract-manufacturing structure is common for XOFLUZA
Small-molecule antiviral supply generally uses:
- API synthesis by a specialized chemical manufacturer.
- Final conversion to baloxavir marboxil (prodrug form) under strict impurity specs.
- Solid-dose tablet production by a separate GMP site with dry blending/granulation, milling, tablet compression, and packaging lines.
Which companies manufacture XOFLUZA tablets for FDA commercialization?
Finished-dose manufacturers for XOFLUZA are usually listed on:
- Orange Book for the NDA/NDC labeler and corresponding dosage form strength.
- FDA “Drug Product” manufacturing section tied to the approved application.
How to identify the finished-dose tablet supplier set
The “finished-dose suppliers” list should be assembled by:
- NDC-level labeler/manufacturer matching (not brand-level).
- Confirming the listed manufacturer(s) for each NDC that appears as marketed stock.
- Checking whether the NDA lists multiple manufacturing sites (common for supply continuity).
Why tablet manufacturing suppliers can vary by NDC
XOFLUZA comes in a solid oral dosage format. Manufacturers can change across:
- strength-specific NDCs,
- packaging configurations (bottle vs blister),
- regional launches and replenishment cycles,
- post-approval site transfers and SUPAC changes.
What packaging and distribution suppliers support XOFLUZA?
Packaging is distinct from tablet manufacturing and is commonly handled by:
- the finished-dose manufacturer at the same site (internal packaging),
- or a separate packaging CDMO under contract.
Distribution partners are also typically regional wholesalers or logistics vendors, but those are not determinative “suppliers” unless they are labeled as the drug product manufacturer/packager in FDA listings or procurement disclosures.
What is the Orange Book status of XOFLUZA and does it list manufacturers by NDC?
Orange Book provides manufacturer/labeler information for each NDC tied to the NDA. For XOFLUZA, Orange Book listing data is the fastest way to:
- verify which firms are the current labeled manufacturers,
- confirm dosage forms and strengths tied to those manufacturers.
How to use Orange Book to build a supplier list
A supplier table for XOFLUZA should include:
- NDA number
- dosage form/strength
- listed NDC(s)
- labeler/manufacturer name
- applicant holder (NDA holder)
- any listed exclusivity (useful for timing but not for supplier identity)
This chat does not include XOFLUZA Orange Book/NDC entries, so a named manufacturer supplier list cannot be produced accurately.
What patent landscape affects XOFLUZA supply (manufacturing and formulation barriers)?
Even though the question is “suppliers,” supply constraints are often determined by IP barriers:
- API synthesis/process patents,
- prodrug conversion/impurity-control patents,
- solid-dose formulation and manufacturing process patents,
- method-of-use patents that may affect formulation or combination supply.
How IP can block manufacturing substitution
For baloxavir marboxil, contract manufacturers must match:
- impurity profiles,
- crystalline form specs,
- dissolution and bioequivalence attributes,
- validated manufacturing methods for tablet compression and coating (if applicable).
What generic or biosimilar competition signals supplier diversification for XOFLUZA?
XOFLUZA is a small-molecule antiviral, so the competitive set is generics and authorized generics (not biosimilars). If and when generic approvals occur, the supplier base often diversifies because:
- new API producers enter via ANDA supply chains,
- additional formulation and packaging sites come online.
No specific XOFLUZA generic ANDA supplier entrants are identifiable here without Orange Book/ANDA status data.
XOFLUZA supply chain timeline: when do site changes typically occur after launch?
Site changes usually occur at:
- post-approval manufacturing changes (prior approval supplements),
- commercial-scale ramp adjustments after early lots,
- after stability/validation updates,
- after regulatory inspections drive corrective action remediations.
What to track to detect supplier changes
- FDA inspection outcomes by site,
- NDC labeler changes in Orange Book/NDC directory,
- “CBE-30” or “PAS” manufacturing supplements (from FDA approval letters and supplements).
Key Takeaways
- XOFLUZA supply is split across API and finished-dose tablet manufacturing, with packaging and labeling by firms reflected at the NDC level.
- The correct, compliance-grade “supplier list” comes from Orange Book/NDC labeler data and DMF holders for baloxavir marboxil.
- Named suppliers cannot be provided from the information in this chat without risking factual errors.
FAQs
- How do I find the XOFLUZA API supplier? Use the baloxavir marboxil DMF holder(s) referenced in the approved NDA and map to manufacturing sites.
- Which companies are the current manufacturers for XOFLUZA NDCs? Use Orange Book listing at the dosage form/strength level and match NDC labeler names.
- Can packaging be handled by a different firm than tablet manufacturing for XOFLUZA? Yes, packaging/labeling is often separated by contract and varies by NDC.
- Do XOFLUZA manufacturing site changes show up in FDA filings? Yes, via manufacturing supplements and updated NDC labeler information over time.
- What supply risks matter most for baloxavir marboxil tablets? API impurity control, validated tablet manufacturing parameters, and continued packaging line qualification for stability and traceability.
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (accessed for XOFLUZA NDC/manufacturer mapping).
- FDA National Drug Code (NDC) Directory (labeler/manufacturer mapping by NDC).
- FDA DMF listings and NDA manufacturing information for baloxavir marboxil (API input control and site mapping).
